![]() |
Progression of advanced breast cancer not delayed by new combination therapy
Adding the antibody therapy ramucirumab to the chemotherapy drug docetaxel did not delay disease progression for patients with HER2-negative, advanced breast cancer, according to results of a placebo-controlled, randomized, phase III clinical trial presented at the 2013 San Antonio Breast Cancer Symposium.
More... |
Re: Progression of advanced breast cancer not delayed by new combination therapy
GDP,
Has Nagourney identified the group that benefits from ramucirumab yet? |
| All times are GMT -7. The time now is 08:21 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021